Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing cancer therapies, including treatments for leukemia and other malignancies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise in slowing lung scarring Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials Results expected Feb 2027 (estimated) May already have reported ↗
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug shows promise in slowing lung scarring
Disease control OngoingThis study tests a drug called axatilimab in 145 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if the drug can slow down the decline in lung function over 26 weeks compared to a placebo. Participants w…
Phase 2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Last-Resort drug access for leukemia patients
Disease control Expanded access (ended)This program provides revumenib (SNDX-5613) to patients with relapsed or refractory acute leukemias who cannot join other studies and have no approved treatments. Participants take the drug orally every 12 hours. The goal is to offer a potential treatment option in a controlled s…
Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC